Dopaminergic Dysregulation, Artistic Expressiveness, and Parkinson's Disease

被引:5
作者
Lopez-Pousa, S. [1 ,2 ]
Lombardia-Fernandez, C. [1 ]
Olmo, J. Garre [1 ,3 ]
Monserrat-Vila, S. [1 ]
Vilalta-Franch, J. [1 ,2 ]
Calvo-Perxas, L. [1 ]
机构
[1] Inst Assistencia Sanitaria, Unitat Recerca, Girona, Spain
[2] Hosp Santa Caterina Salt, Unitat Valoracio Memoria & Demencies, Salt, Spain
[3] Univ Girona, Dept Psicol, Girona, Spain
关键词
Dopamine dysregulation; Parkinson's disease; Art;
D O I
10.1159/000343946
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The most frequent behavioral manifestations in Parkinson's disease (PD) are attributed to the dopaminergic dysregulation syndrome (DDS), which is considered to be secondary to the iatrogenic effects of the drugs that replace dopamine. Over the past few years some cases of patients improving their creative abilities after starting treatment with dopaminergic pharmaceuticals have been reported. These effects have not been clearly associated to DDS, but a relationship has been pointed out. Methods: Case study of a patient with PD. The evolution of her paintings along medication changes and disease advance has been analyzed. Results: The patient showed a compulsive increase of pictorial production after the diagnosis of PD was made. She made her best paintings when treated with cabergolide, and while painting, she reported a feeling of well-being, with loss of awareness of the disease and reduction of physical limitations. Conclusions: Dopaminergic antagonists (DA) trigger a dopaminergic dysfunction that alters artistic creativity in patients having a predisposition for it. The development of these skills might be due to the dopaminergic overstimulation due to the therapy with DA, which causes a neurophysiological alteration that globally determines DDS.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 15 条
[1]   Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field [J].
Ambermoon, Polly ;
Carter, Adrian ;
Hall, Wayne D. ;
Dissanayaka, Nadeeka N. W. ;
O'Sullivan, John D. .
ADDICTION, 2011, 106 (02) :283-293
[2]   Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder [J].
Beucke, Jan C. ;
Uhl, Idun ;
Plotkin, Michail ;
Winter, Christine ;
Assion, Hans-Joerg ;
Endrass, Tanja ;
Amthauer, Holger ;
Kupsch, Andreas ;
Juckel, Georg .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2010, 11 (06) :781-787
[3]   Outcomes of Patients with Parkinson Disease and Pathological Gambling [J].
Bharmal, A. ;
Lu, C. ;
Quickfall, J. ;
Crockford, D. ;
Suchowersky, O. .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2010, 37 (04) :473-477
[4]   Artistic productivity and creative thinking in Parkinson's disease [J].
Canesi, M. ;
Rusconi, M. L. ;
Isaias, I. U. ;
Pezzoli, G. .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) :468-472
[5]   Art produced by a patient with Parkinson's disease [J].
Chatterjee, Anjan ;
Hamilton, Roy H. ;
Amorapanth, Prin X. .
BEHAVIOURAL NEUROLOGY, 2006, 17 (02) :105-108
[6]   Untreated Depressive Symptoms Among Cognitively-Intact, Community Dwelling Filipino Patients With Parkinson Disease [J].
Go, Criscely L. ;
Rosales, Raymond L. ;
Joya-Tanglao, Michelle ;
Fernandez, Hubert H. .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2011, 121 (03) :137-141
[7]  
Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1
[8]  
Laneyrie-Dagen N, 2006, LEER LA PINTURA, pX
[9]   Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? [J].
Lawrence, AD ;
Evans, AH ;
Lees, AJ .
LANCET NEUROLOGY, 2003, 2 (10) :595-604
[10]  
Lopez-Pousa S., 2012, REV ALZHEIMER, V50, P20, DOI [10.5538/1137-1242.2012.50.20, DOI 10.5538/1137-1242.2012.50.20]